Robin Gottfried
Nurse Practitioner · Sycamore, OHNPI 1699167536
Payments from drug & device makers
Across 67 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$171
- AbbVie$125
- Novo Nordisk$122
- Bayer$117
- Amgen$106
- Boston Scientific$81
- plus $389 from 17 others
What the payments were for
- Food & beverage$1,111100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $171 |
| AbbVie | 8 | $125 |
| Novo Nordisk | 9 | $122 |
| Bayer | 8 | $117 |
| Amgen | 7 | $106 |
| Boston Scientific | 2 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Lilly USA, LLC | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Merck | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Novartis | 2 | $26 |
| Exact Sciences | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Pfizer | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| GSK | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,111 in reported general payments places this provider in the 85th percentile of 4,700 nurse practitioner providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $34,620 |
| JardianceEmpagliflozin | 21 | $24,717 |
| JanuviaSitagliptin Phosphate | 18 | $22,485 |
| FarxigaDapagliflozin Propanediol | 13 | $13,964 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $5,953 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,730 |
| Ezetimibe | 49 | $2,207 |
| Duloxetine Hcl | 119 | $2,181 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,085 |
| Potassium Chloride | 86 | $1,977 |
| Rosuvastatin Calcium | 206 | $1,957 |
| Levothyroxine Sodium | 181 | $1,840 |
| Metoprolol Succinate | 193 | $1,681 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,675 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $1,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $34,62043 claims |
| MerckJanuvia | $32 | $22,48518 claims |
| AstraZenecaFarxiga, Symbicort | $171 | $19,69430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Sycamore
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.